
Torrent (TORNTPHARM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
31.3B
Gross Profit
23.5B
75.26%
Operating Income
8.3B
26.57%
Net Income
5.5B
17.52%
EPS (Diluted)
₹16.19
Balance Sheet Metrics
Total Assets
149.9B
Total Liabilities
74.0B
Shareholders Equity
75.9B
Debt to Equity
0.97
Cash Flow Metrics
Revenue & Profitability Trend
Torrent Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 113.2B | 105.6B | 94.6B | 84.2B | 78.9B |
Cost of Goods Sold | 28.8B | 27.9B | 28.3B | 25.4B | 22.4B |
Gross Profit | 84.3B | 77.7B | 66.4B | 58.8B | 56.5B |
Gross Margin % | 74.5% | 73.6% | 70.1% | 69.9% | 71.7% |
Operating Expenses | |||||
Research & Development | 304.2M | 247.3M | 312.7M | 386.5M | 251.8M |
Selling, General & Administrative | 20.0B | 19.0B | 16.4B | 14.4B | 13.1B |
Other Operating Expenses | 5.7B | 5.6B | 5.1B | 4.4B | 4.4B |
Total Operating Expenses | 26.0B | 24.9B | 21.9B | 19.2B | 17.7B |
Operating Income | 29.3B | 25.7B | 21.4B | 17.7B | 18.2B |
Operating Margin % | 25.9% | 24.4% | 22.6% | 21.0% | 23.1% |
Non-Operating Items | |||||
Interest Income | 201.9M | 114.8M | 147.8M | 71.5M | 50.7M |
Interest Expense | 2.5B | 3.5B | 3.3B | 2.5B | 3.5B |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 26.7B | 23.5B | 18.5B | 12.3B | 15.3B |
Income Tax | 7.6B | 7.0B | 6.0B | 4.5B | 2.7B |
Effective Tax Rate % | 28.5% | 29.6% | 32.6% | 36.6% | 18.0% |
Net Income | 19.1B | 16.6B | 12.5B | 7.8B | 12.5B |
Net Margin % | 16.9% | 15.7% | 13.2% | 9.2% | 15.9% |
Key Metrics | |||||
EBITDA | 37.3B | 34.1B | 28.4B | 26.2B | 25.2B |
EPS (Basic) | ₹56.47 | ₹48.94 | ₹36.79 | ₹22.96 | ₹36.99 |
EPS (Diluted) | ₹56.47 | ₹48.94 | ₹36.79 | ₹22.96 | ₹36.99 |
Basic Shares Outstanding | 338445440 | 338445440 | 338445440 | 338445440 | 338445440 |
Diluted Shares Outstanding | 338445440 | 338445440 | 338445440 | 338445440 | 338445440 |
Income Statement Trend
Torrent Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 5.7B | 8.4B | 5.1B | 4.0B | 5.7B |
Short-term Investments | 1.1B | 1.7B | 2.1B | 1.8B | 1.7B |
Accounts Receivable | 18.7B | 18.4B | 19.4B | 16.3B | 15.2B |
Inventory | 25.4B | 22.8B | 22.3B | 24.6B | 26.8B |
Other Current Assets | 3.4B | 3.0B | 3.0B | 3.1B | 4.5B |
Total Current Assets | 56.2B | 56.1B | 53.1B | 51.6B | 55.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 3.0B | 2.8B | 2.5B | 2.6B | 2.2B |
Goodwill | 49.4B | 52.6B | 57.6B | 40.7B | 46.7B |
Intangible Assets | 42.6B | 45.8B | 50.9B | 35.5B | 39.9B |
Long-term Investments | 48.4M | 43.8M | 0 | 246.0M | 108.0M |
Other Non-Current Assets | 420.0M | 150.0M | 220.0M | 260.0M | 240.0M |
Total Non-Current Assets | 93.7B | 94.5B | 97.0B | 79.3B | 85.5B |
Total Assets | 149.9B | 150.6B | 150.1B | 131.0B | 140.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 18.2B | 20.9B | 16.8B | 16.7B | 20.7B |
Short-term Debt | 18.6B | 23.5B | 28.2B | 19.1B | 19.1B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 1.4B | 1.3B | 1.0B | 990.0M | 1.3B |
Total Current Liabilities | 47.2B | 54.3B | 54.5B | 44.2B | 48.9B |
Non-Current Liabilities | |||||
Long-term Debt | 13.4B | 16.7B | 25.5B | 21.6B | 29.6B |
Deferred Tax Liabilities | 8.3B | 6.6B | 4.0B | 1.9B | 0 |
Other Non-Current Liabilities | - | 10.0M | 20.0M | 40.0M | 50.0M |
Total Non-Current Liabilities | 26.8B | 27.8B | 33.7B | 27.3B | 33.5B |
Total Liabilities | 74.0B | 82.0B | 88.1B | 71.5B | 82.4B |
Equity | |||||
Common Stock | 1.7B | 1.7B | 1.7B | 846.2M | 846.2M |
Retained Earnings | - | 39.4B | 33.0B | 29.2B | 28.1B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 75.9B | 68.6B | 62.0B | 59.5B | 58.4B |
Key Metrics | |||||
Total Debt | 32.0B | 40.2B | 53.7B | 40.7B | 48.7B |
Working Capital | 9.1B | 1.9B | -1.3B | 7.5B | 6.3B |
Balance Sheet Composition
Torrent Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 26.7B | 23.5B | 18.5B | 12.3B | 15.3B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -2.0B | 45.3M | 398.2M | 405.2M | -4.7B |
Operating Cash Flow | 27.0B | 26.1B | 22.1B | 20.0B | 14.1B |
Investing Activities | |||||
Capital Expenditures | -5.9B | -3.0B | -4.2B | -2.0B | -3.3B |
Acquisitions | - | 0 | -20.0B | 0 | - |
Investment Purchases | -117.5M | - | -603.8M | -347.9M | -1.6B |
Investment Sales | 455.4M | 1.2B | 474.0M | 267.0M | 428.0M |
Investing Cash Flow | -5.6B | -1.8B | -24.3B | -2.0B | -4.5B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -10.8B | -10.2B | -8.6B | -6.8B | -3.4B |
Debt Issuance | - | 0 | 14.0B | 0 | 9.0B |
Debt Repayment | -9.3B | -12.4B | -9.7B | -10.3B | -14.4B |
Financing Cash Flow | -24.0B | -23.8B | 4.0B | -14.9B | -12.6B |
Free Cash Flow | 19.7B | 28.3B | 17.9B | 16.0B | 16.7B |
Net Change in Cash | -2.6B | 445.4M | 1.8B | 3.0B | -3.1B |
Cash Flow Trend
Torrent Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
60.57
Forward P/E
39.97
Price to Book
15.93
Price to Sales
10.22
PEG Ratio
3.94
Profitability Ratios
Profit Margin
16.92%
Operating Margin
26.15%
Return on Equity
25.18%
Return on Assets
12.75%
Financial Health
Current Ratio
1.19
Debt to Equity
42.81
Beta
0.13
Per Share Data
EPS (TTM)
₹58.99
Book Value per Share
₹224.28
Revenue per Share
₹349.64
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
torntpharm | 1.2T | 60.57 | 15.93 | 25.18% | 16.92% | 42.81 |
Sun Pharmaceutical | 3.8T | 36.63 | 5.27 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 68.71 | 10.59 | 14.64% | 23.89% | 0.03 |
Cipla | 1.2T | 22.27 | 3.85 | 16.85% | 19.62% | 1.40 |
Mankind Pharma | 1.0T | 53.19 | 7.10 | 13.67% | 14.66% | 58.43 |
Dr. Reddy's | 1.0T | 18.01 | 2.91 | 17.71% | 16.99% | 13.75 |
Financial data is updated regularly. All figures are in the company's reporting currency.